Skip header and navigation

25 records – page 1 of 2.

Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc223

Vanstone, J; Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc226

Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc38

Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc39

Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc43

Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc48

Duncan, V. What sampling method is most appropriate for population testing? 2020 Apr 23; Document no.: LAB042201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc52

Howell-Spooner, B. What frequency of repeat population screening will be required? 2020 Apr 23; Document no.: LAB042202-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 40 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc53

Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56

Williams-Roberts, H; Lee, S; Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS CoV-2? 2020 Apr 27; Document no.: INF042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc57

Vanstone, J; Reeder, B; Duncan, V. What sampling method is most appropriate for population testing? 2020 Apr 23; Document no.: LAB042201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc64

Wang, H; Reeder, B; Howell-Spooner, B. What frequency of repeat population screening will be required? 2020 Apr 25; Document no.: LAB042202 RR. In: COVID19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc65

Howell-Spooner, B; Dalidowicz, M; Boden, C. How is "compassionate visit" defined and operationalized in the context of an infectious outbreak or pandemic? 2020 Apr 28; Document no.: LTC042402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 7 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc67

Boden, C; Ellsworth, C. What are best practices for engaging family care providers during a pandemic? 2020 Apr 30; Document no.: LTC042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 32 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc69

Tupper, S; Ward, H; Howell-Spooner, B; Dalidowicz, M; Boden, C. How is "compassionate visit" defined and operationalized in the context of an infectious outbreak or pandemic in long-term care? 2020 May 1; Document no.: LTC042402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc70

Dalidowicz, M; Howell-Spooner, B. What are the impacts on the family unit from visitation restrictions during an infectious disease outbreak and how can we support the families? 2020 May 1; Document no.: LTC042403-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc71

Tupper, S; Ward, H; Dalidowicz, M; Boden, C; Ellsworth, C; What are best practices for engaging family care providers during a pandemic? 2020 Apr 16; Document no.: LTC042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc73

Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 12; Document no.: EPM050901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 48 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc79

Tupper, S; Ward, H; Howell-Spooner, B; Dalidowicz, M; What are the impacts on the family unit from visitation restrictions during an infectious disease outbreak and how can we support the families? 2020 May 14; Document no.: LTC042403 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 38 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc80

Williams-Roberts, H; Groot, G; Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 17; Document no.: EPM050901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc87

25 records – page 1 of 2.